N@N

Anika Therapeutics to Present at NYSSA Biotech and Specialty Pharmaceuticals Conference

^{Published on 2010-11-23 06:05:41 - Market Wire}
 

BEDFORD, Mass.--([ BUSINESS WIRE ])--Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that Kevin Quinlan, chief financial officer, will be presenting at the New York Society of Security Analysts (NYSSA) Biotech and Specialty Pharmaceuticals Conference on Tuesday, November 30, 2010. A live audio webcast of the 2:05 p.m. (ET) presentation may be accessed via the aInvestorsa section of Anikaa™s website at [ www.anikatherapeutics.com ]. An archive of the presentation also will be available on the website. At the conference, Mr. Quinlan will discuss the companya™s business highlights, including the integration of its FAB acquisition.

About Anika Therapeutics, Inc.

Headquartered in Bedford, Mass., [ Anika Therapeutics, Inc ]. develops, manufactures and commercializes therapeutic products for tissue protection, healing, repair and regeneration. These products are based on [ hyaluronic acid (HA) ], a naturally occurring, biocompatible polymer found throughout the body. Anikaa™s products range from orthopedic/joint health solutions led by [ ORTHOVISC ]^®, a treatment for osteoarthritis of the knee; to surgical aids in the [ ophthalmic ] and [ anti-adhesion ] fields. The company also offers [ aesthetic dermal fillers ] for the correction of facial wrinkles. Anikaa™s Italian subsidiary, Fidia Advanced Biopolymers, S.r.l (FAB), provides complementary HA products in orthopedic/joint health and anti-adhesion, as well as therapeutics in new areas such as advanced wound treatment and ear, nose and throat care. FABa™s regenerative tissue technology advances Anikaa™s vision to offer therapeutic products that go beyond pain relief to protect and restore damaged tissue.